Type 2 DiabetesNCT02726256
G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)
An observational study of Type 2 Diabetes and Impaired Glucose Intolerance, run by Yonsei University.
Trial summary
The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. Diabetes develops due to glucose intolerance. Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. Read more about this study
- Who is it for?
- Ages 20 to 100 years
- Conditions the study is for
- Type 2 Diabetes, Impaired Glucose Intolerance
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- Jan 2007to Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with either type 2 diabetes or impaired glucose toloerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
Who may be able to join
- Patients older than 20 years old who has visited Gangnam severance hospital since January 2007.
- Patients with either diabetes or impaired glucose tolerance
- Patients with at least 6 months of follow-up period
Who cannot join
- 1. Patients with gestational diabetes, any active stage of cancer and severe disability
Trial locations and contacts
No sites are listed yet.
About this study
The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. Diabetes develops due to glucose intolerance. Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. This study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.
- Conditions
- Type 2 Diabetes, Impaired Glucose Intolerance
- Keywords
- Diabetes, DM complication
- Medical subject headings
- Diabetes Mellitus, Type 2, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Diabetes and Impaired glucose Tolerance (G-CREDIT) | Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Life style assessment - Past medical history - Smoking, alcohol history - Sleep, exercise, daily activity check - Diet - Reproductive status (Women only) - Socioeconomic status
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Past medical history
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Smoking, alcohol history
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Sleep, exercise, daily activity check
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Diet
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Reproductive status (Women only)
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Socioeconomic status
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Anthropometric measurements : Height, weight, waist circumference, pulse rate, blood pressure
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
SMA, TG, HDL, LDLM apoA, apoB
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
PC2hrs, HbA1C, Insulin, C-peptide (AC, PC2hr), hs-CRP
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Urine protein, albumin, creatinine
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
EKG, Neurometer, Chest PA, Abdominal sonography
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Fundus photography, fat computed tomography
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
HOMA-IR, HOMA-β
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Measured: an expected average of 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2016 (estimated)
- Study startJan 2007
- Primary completionFeb 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by Yonsei UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yonsei University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02726256
- Sponsor's protocol ID
- 3-2010-0195
- Status last verified
- Apr 2016
- First submitted
- 27 Mar 2016
- Last updated
- 18 Apr 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: This study has a plan to share data
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)
- ClinicalTrials.gov ID
- NCT02726256
- Acronym / sponsor ID
- 3-2010-0195
- Conditions
- Type 2 Diabetes, Impaired Glucose Intolerance
- Keywords
- Diabetes, DM complication
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Yonsei UniversityUniversity, hospital or other
- Study start
- Jan 2007
- Primary completion
- Feb 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 1 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prevalence of type 2 diabetes has consistently increased and type 2 diabetes can cause many types of vascular complications. Diabetes develops due to glucose intolerance. Early detection and intervention in the stage of glucose intolerance makes it afford to prevent overt diabetes and its complications. This study was designed to make a cohort of korean patients with glucose intolerance to construct a long term database about clinical characteristics of these patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Diabetes and Impaired glucose Tolerance (G-CREDIT) | – | –Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up. |
Who may qualify
- Ages
- 20 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with either type 2 diabetes or impaired glucose toloerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
Key inclusion criteria (3 listed)
- Patients older than 20 years old who has visited Gangnam severance hospital since January 2007.
- Patients with either diabetes or impaired glucose tolerance
- Patients with at least 6 months of follow-up period
Key exclusion criteria (1 listed)
- 1. Patients with gestational diabetes, any active stage of cancer and severe disability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Life style assessment - Past medical history - Smoking, alcohol history - Sleep, exercise, daily activity check - Diet - Reproductive status (Women only) - Socioeconomic status
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Past medical history
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Smoking, alcohol history
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Sleep, exercise, daily activity check
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Diet
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Reproductive status (Women only)
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Socioeconomic status
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Anthropometric measurements : Height, weight, waist circumference, pulse rate, blood pressure
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
SMA, TG, HDL, LDLM apoA, apoB
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
PC2hrs, HbA1C, Insulin, C-peptide (AC, PC2hr), hs-CRP
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Urine protein, albumin, creatinine
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
EKG, Neurometer, Chest PA, Abdominal sonography
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Fundus photography, fat computed tomography
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
HOMA-IR, HOMA-β
Time frame: an expected average of 12 weeks
Measuring above all, investigators plan to investigate how clinical parameters help to predict and prevent diabetic vascular complications
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2016.
- Individual participant dataSharing planned: Yes. This study has a plan to share data
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes and Impaired Glucose Intolerance, run by Yonsei University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chul Woo Ahn, MD (82-02-2019-3339, acw@yuhs.ac), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Life style assessment - Past medical history - Smoking, alcohol history - Sleep, exercise, daily activity check - Diet - Reproductive status (Women only) - Socioeconomic status (time frame: an expected average of 12 weeks). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2016.